Anthropic unveils Claude Sonnet 5, a groundbreaking AI model offering enhanced agentic capabilities at lower costs. Targeting developers and businesses, the model aims to outperform competitors like GPT-5.5 and Gemini Pro while reducing operational expenses.

The 246th LWiAI podcast breaks down Google’s Gemini 3.5 flash model, the multimodal Gemini Omni video engine, Elon Musk’s lost lawsuit, and OpenAI’s breakthrough on an 80‑year‑old Erdős geometry problem. We unpack the technical specs, market ripples, and what developers should watch next.

A new arXiv study shows OpenEvidence's specialized clinical tool beats top general‑purpose models (Claude Opus 4.8, Gemini 3.1 Pro, GPT‑5.5) on 620 real‑world point‑of‑care questions. Physicians across 30 specialties rated the specialized tool higher on accuracy, utility, source quality, verifiability and completeness.

OpenAI co‑founder Greg Brockman testified that the company expects to spend $50 billion on compute this year, a figure tied to massive cloud and hardware deals. The revelation spotlights the economics of large‑scale AI and raises questions about profitability and investor expectations.

OpenAI introduces ATHENA-R1, an AI agent for treatment reasoning that outperforms language models and tool-use systems. Trained on 212 biomedical tools, ATHENA-R1 achieves 94.7% accuracy on open-ended drug reasoning and 82.9% on treatment reasoning. This breakthrough has significant implications for the healthcare industry and AI research.

OpenAI introduces IMCBench, a benchmark for multimodal large language models in image-grounded medical conversations, evaluating safety, accuracy, and uncertainty in diagnosis. The benchmark tests eight models, with Claude Opus 4.6 achieving the highest overall score. The results highlight the need for multi-dimensional evaluation frameworks in medical AI.